Advertisement

Journal of Neurology

, Volume 252, Issue 3, pp 291–299 | Cite as

Adult medulloblastoma

Prognostic factors and response to therapy at diagnosis and at relapse
  • Ulrich Herrlinger*Email author
  • A. Steinbrecher*
  • J. Rieger
  • P. Hau
  • R.-D. Kortmann
  • R. Meyermann
  • M. Schabet
  • M. Bamberg
  • J. Dichgans
  • U. Bogdahn
  • M. Weller
ORIGINAL COMMUNICATION

Abstract

Adult medulloblastoma is a rare tumor with few retrospective studies published so far. The role of adjuvant chemotherapy or chemotherapy at relapse is unclear. This study reports therapy and outcome in all adult (≥ 16 years old) medulloblastoma (n = 34) and supratentorial primitive neuroectodermal tumor (PNET) patients (n = 2) treated in 2 neuro–oncological centers between 1976 and 2002. The median age was 24.5 years (range 16–76). After resection, 16 patients were treated with craniospinal radiotherapy alone, 20 patients also received adjuvant chemotherapy (8 vincristine, CCNU, cisplatin; 7 methotrexate alone or methotrexate/vincristine–based polychemotherapy; 5 other protocols). Median survival in the whole cohort was 126 months (2+ – 200+ months). Five–year and 10–year survival rates were 79 % and 56%. Adjuvant chemotherapy was associated with a non–significant trend to prolonged survival (relative risk (RR) 1.89; p = 0.068). The median progression–free survival (PFS) after primary therapy was 83 months. At relapse, 10 of 12 evaluable patients achieved a complete response upon second–line therapy. The median survival times from first (n = 17) and second relapse (n = 9) were 21 months (0–67+ months; 5/17 without second relapse) and 20 months (1–29 months). Cox regression analysis revealed the infiltration of the floor of the 4th ventricle at diagnosis as the only therapy–independent prognostic factor (RR 0.48; p = 0.03). In conclusion, adjuvant chemotherapy may prolong survival in adult medulloblastoma patients. Moreover, second–line therapy may be beneficial for these patients. As in pediatric medulloblastoma patients, primary infiltration of the floor of the 4th ventricle indicates a poor prognosis.

Key words

adult medulloblastoma radiotherapy chemotherapy primitive neuroectodermal tumor secondline therapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Abacioglu U, Uzel O, Sengoz M, Turkan S, Ober A (2002) Medulloblastoma in adults: treatment results and prognostic factors. Int J Radiat Oncol Biol Phys 54:855–860Google Scholar
  2. 2.
    Albright AL, Wisoff JH, Zeltzer PM, et al. (1996) Effects of medulloblastoma resections on outcome in children: a report from the Children’s Cancer Group. Neurosurgery 38:265–271Google Scholar
  3. 3.
    Bloom HJ, Bessell EM (1990) Medulloblastoma in adults: a review of 47 patients treated between 1952 and 1981. Int J Radiat Oncol Biol Phys 18:763–772Google Scholar
  4. 4.
    Brandes AA, Palmisano V, Monfardini S (1999) Medulloblastoma in adults: clinical characteristics and treatment. Cancer Treat Rev 25:3–12Google Scholar
  5. 5.
    Carrie C, Lasset C, Alapetite C, et al. (1994) Multivariate analysis of prognostic factors in adult patients with medulloblastoma. Cancer 74:2352–2360Google Scholar
  6. 6.
    Chan AW, Tarbell NJ, Black PM, et al. (2000) Adult medulloblastoma: prognostic factors and patterns of relapse. Neurosurgery 47:623–633Google Scholar
  7. 7.
    Chang CH, Housepian EM, Herbert CJ (1969) An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 93:1351–1359PubMedGoogle Scholar
  8. 8.
    Dunkel IJ, Boyett JM, Yates A, et al. (1998) High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children’s Cancer Group J Clin Onco 16:222–228Google Scholar
  9. 9.
    Evans AE, Jenkin RD, Sposto R, et al. (1990) The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 72:572–582Google Scholar
  10. 10.
    Freeman CR, Taylor RE, Kortmann RD, Carrie C (2002) Radiotherapy for medulloblastoma in children: a perspective on current international clinical research efforts. Med Pediatr Oncol 39:99–108Google Scholar
  11. 11.
    Frost PJ (1995) Medulloblastoma in adults. Int J Radiat Oncol Biol Phys 32:951–957Google Scholar
  12. 12.
    Giangaspero F, Bigner SH, Kleihues P, Pietsch T, Trojanowski JQ (2000) Medulloblastoma. In: Kleihues P, Cavenee WK. Tumours of the nervous system. Lyon: IARCPRess, pp 129–137Google Scholar
  13. 13.
    Giordana MT, Schiffer P, Lanotte M, Girardi P, Chio A (1999) Epidemiology of adult medulloblastoma. Int J Cancer 80:689–692PubMedGoogle Scholar
  14. 14.
    Greenberg HS, Chamberlain MC, Glantz MJ, Wang S (2001) Adult medulloblastoma: multiagent chemotherapy. Neurooncol 3:29–34Google Scholar
  15. 15.
    Jenkin D, Shabanah MA, Shail EA, et al. (2000) Prognostic factors for medulloblastoma. Int J Radiat Oncol Biol Phy 47:573–584Google Scholar
  16. 16.
    Kaplan EL, Meier P (1958) Non-parametric estimations from incomplete observations. J Am Stat Assoc 53:457–481Google Scholar
  17. 17.
    Kortmann RD, Kuhl J, Timmermann B, et al. (2000) Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT 91. Int J Radiat Oncol Biol Phys 46:269–279Google Scholar
  18. 18.
    Macdonald DR, Cascino TL, Schold SC, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280Google Scholar
  19. 19.
    Packer RJ, Goldwein J, Nicholson HS, et al. (1999) Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children’s Cancer Group Study. J Clin Oncol 17:2127–2136Google Scholar
  20. 20.
    Packer RJ, Sutton LN, Elterman R, et al. (1994) Outcome for children with medulloblastoma treated with radiation and cisplatin,CCNU, and vincristine chemotherapy. J Neurosurg 81:690–698Google Scholar
  21. 21.
    Paulino AC, Melian E (1999) Medulloblastoma and supratentorial primitive neuroectodermal tumors: an institutional experience. Cancer 86:142–148Google Scholar
  22. 22.
    Peterson K, Walker RW (1995) Medulloblastoma/ primitive neuroectodermal tumor in 45 adults. Neurology 45:440–442Google Scholar
  23. 23.
    Prados MD, Warnick RE, Wara WM, Larson DA, Lamborn K, Wilson CB (1995) Medulloblastoma in adults. Int J Radiat Oncol Biol Phys 32:1145–1152Google Scholar
  24. 24.
    Rorke LB, Hart MN, McLendon RE (2000) Supratentorial primitive neuroectodermal tumor (PNET). In: Kleihues P, Cavenee WK. Tumours of the nervous system. Lyon: IARCPRess, pp 141–144Google Scholar
  25. 25.
    Tait DM, Thornton-Jones H, Bloom HJ, Lemerle J, Morris-Jones P (1990) Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cance 26:464–469Google Scholar
  26. 26.
    Taylor RE, Bailey CC, Robinson K, et al. (2003) Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 Study. J Clin Oncol 21:1581–1591Google Scholar
  27. 27.
    Thomas PR, Deutsch M, Kepner JL, et al. (2000) Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 18:3004–3011Google Scholar
  28. 28.
    Timmermann B, Kortmann RD, Kuhl J, et al. (2002) Role of radiotherapy in the treatment of supratentorial primitive neuroectodermal tumors in childhood: results of the prospective German brain tumor trials HIT 88/89 and 91. J Clin Oncol 20:842–849Google Scholar
  29. 29.
    Zeltzer PM, Boyett JM, Finlay JL, et al. (1999) Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol 17:832–845Google Scholar
  30. 30.
    Zia MI, Forsyth P, Chaudhry A, Russell J, Stewart DA (2002) Possible benefits of high-dose chemotherapy and autologous stem cell transplantation for adults with recurrent medulloblastoma. Bone Marrow Transplant 30:565–569Google Scholar

Copyright information

© Steinkopff Verlag 2005

Authors and Affiliations

  • Ulrich Herrlinger*
    • 4
    Email author
  • A. Steinbrecher*
    • 1
  • J. Rieger
    • 4
  • P. Hau
    • 1
  • R.-D. Kortmann
    • 2
  • R. Meyermann
    • 3
  • M. Schabet
    • 4
  • M. Bamberg
    • 2
  • J. Dichgans
    • 4
  • U. Bogdahn
    • 1
  • M. Weller
    • 4
  1. 1.Department of NeurologyUniversity of RegensburgRegensburgGermany
  2. 2.Department of Radiation OncologyUniversity of TübingenTübingenGermany
  3. 3.Institute for Brain ResearchUniversity of TübingenTübingenGermany
  4. 4.Department of NeurologyHertie Institute for Clinical Brain Research University of Tübingen Medical SchoolTübingenGermany

Personalised recommendations